MA46988A1 - Formulation liquide d'anticorps anti-tnf alpha - Google Patents

Formulation liquide d'anticorps anti-tnf alpha

Info

Publication number
MA46988A1
MA46988A1 MA46988A MA46988A MA46988A1 MA 46988 A1 MA46988 A1 MA 46988A1 MA 46988 A MA46988 A MA 46988A MA 46988 A MA46988 A MA 46988A MA 46988 A1 MA46988 A1 MA 46988A1
Authority
MA
Morocco
Prior art keywords
liquid formulation
tnf alpha
alpha antibodies
antibodies
tnf
Prior art date
Application number
MA46988A
Other languages
English (en)
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA46988A1 publication Critical patent/MA46988A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

La présente invention concerne une formulation liquide d'un anticorps anti-tnf alpha, en particulier l'adalimumab.
MA46988A 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha MA46988A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (fr) 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha

Publications (1)

Publication Number Publication Date
MA46988A1 true MA46988A1 (fr) 2020-06-30

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46988A MA46988A1 (fr) 2017-03-16 2018-03-16 Formulation liquide d'anticorps anti-tnf alpha

Country Status (15)

Country Link
JP (2) JP7109849B2 (fr)
KR (2) KR20180106974A (fr)
CN (1) CN110621303A (fr)
AU (1) AU2018236651B2 (fr)
BR (1) BR112019019162A2 (fr)
CO (1) CO2019010860A2 (fr)
MA (1) MA46988A1 (fr)
MX (1) MX2019010895A (fr)
MY (1) MY197202A (fr)
NZ (1) NZ757965A (fr)
PH (1) PH12019502075A1 (fr)
RU (1) RU2756619C2 (fr)
UA (1) UA123847C2 (fr)
WO (1) WO2018169348A1 (fr)
ZA (1) ZA201906696B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172002A1 (fr) * 2019-02-18 2020-08-27 Eli Lilly And Company Formulation d'anticorps thérapeutique
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2637690B1 (fr) * 2010-11-11 2016-09-21 AbbVie Biotechnology Ltd FORMULATION LIQUIDE D'ANTICORPS ANTI-TNFalpha HAUTEMENT CONCENTRÉE
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CN104159614A (zh) * 2012-03-07 2014-11-19 卡迪拉保健有限公司 TNF-α抗体的药物制剂
JP6463268B2 (ja) * 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
US20150368333A1 (en) 2013-01-24 2015-12-24 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
EP2968538A1 (fr) 2013-03-15 2016-01-20 Bayer HealthCare LLC Formulations d'anticorps anti-récepteurs de prolactine
WO2015134406A1 (fr) 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Préparations aqueuses stables de protéine recombinée
US10688187B2 (en) 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
SI2946765T1 (sl) * 2014-05-23 2016-11-30 Ares Trading S.A. Tekoči farmacevtski sestavek
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016120413A1 (fr) * 2015-01-28 2016-08-04 Mabxience S.A. Formulations pharmaceutiques pour des anticorps anti-tnf-alpha
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

Also Published As

Publication number Publication date
CN110621303A (zh) 2019-12-27
BR112019019162A2 (pt) 2020-04-14
PH12019502075A1 (en) 2020-09-14
KR20200096472A (ko) 2020-08-12
JP2022097600A (ja) 2022-06-30
NZ757965A (en) 2022-07-01
MY197202A (en) 2023-05-31
ZA201906696B (en) 2020-08-26
AU2018236651A1 (en) 2019-10-31
KR102342292B1 (ko) 2021-12-24
RU2756619C2 (ru) 2021-10-04
CO2019010860A2 (es) 2020-01-17
JP7109849B2 (ja) 2022-08-01
AU2018236651B2 (en) 2020-12-10
WO2018169348A1 (fr) 2018-09-20
UA123847C2 (uk) 2021-06-09
RU2019130728A3 (fr) 2021-04-16
KR20180106974A (ko) 2018-10-01
MX2019010895A (es) 2019-11-05
JP2020510079A (ja) 2020-04-02
RU2019130728A (ru) 2021-04-16

Similar Documents

Publication Publication Date Title
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
MX2018012648A (es) Preparaciones que contienen anticuerpos.
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA38632A1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
MA38322A1 (fr) Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
IN2012DN05237A (fr)
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
EA201991701A1 (ru) Состав на основе моноклонального антитела к rsv
CO6270369A2 (es) Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MA38413A1 (fr) Anticorps pan-elr+ cxc chimiokine
EA201992027A1 (ru) Водный состав антитела против pd-l1
PH12014501985B1 (en) Il-17 antibody formulation
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation